HCC rates increasing in US, most common tumor in East Asia, Africa
Trying to get a handle on the potential patient population w/ advanced HCC that weren't helped by Sorafenib. From what I've read, once the HCC gets "advanced," there is not a lot of hope for those suffering. Some info I found - - -
Excerpt from the New England Journal of Medicine from July 2008:
Sorafenib in Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma is a major health problem, accounting for more than 626,000 new cases per year worldwide.1 The incidence of hepatocellular carcinoma is increasing in the United States and Europe, and it is the third highest cause of cancer-related death globally, behind only lung and stomach cancers.1 In the West, the disease is diagnosed in 30 to 40% of all patients at early stages and is amenable to potentially curative treatments, such as surgical therapies (resection and liver transplantation) and locoregional procedures (radiofrequency ablation).2 Five-year survival rates of up to 60 to 70% can be achieved in well-selected patients.2 However, disease that is diagnosed at an advanced stage or with progression after locoregional therapy has a dismal prognosis, owing to the underlying liver disease and lack of effective treatment options.2-4 No systemic therapy has improved survival in patients with advanced hepatocellular carcinoma.
and this excerpt from the British Journal of Cancer:
Hepatocellular carcinoma (HCC) is the second most common cause of cancer death in men and the sixth in women worldwide (Jemal et al, 2011). Hepatocellular carcinoma is the most common tumour in certain parts of the world, particularly in East Asia, Africa, and certain countries of South America. This tumour is less frequent in Europe and in the United States, but has become the fastest rising cancer in the United States (Jemal et al, 2011). In the United States alone, it is estimated that 24 120 new cases were diagnosed and there were 17 430 deaths from HCC in 2010 (Jemal et al, 2010), a 27% increase in the number of new cases since 2004 (Jemal et al, 2004). The prognosis of patients suffering from advanced HCC is poor with an average survival of fewer than 6 months (Kassianides and Kew, 1987; Jemal et al, 2011).
Thanks for info east! Sorafenib is now available in generic channel in India. Soranefib was approved in 2007 and the price appears to have fallen from $5,500 per month to $175 per month (at least in India) - ouch for Bayer/Onyx.